Market Analysis: Global Uveitis Drug Market

Global uveitis drug market is rising gradually to an estimated value of USD 736.99million by 2026 registering a substantial CAGR of 7.2% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients, increasing prevalence of chronic diseases such as trauma to the eye, rheumatoid arthritis, increasing personal disposable income, and high expenditure in healthcare sector and favorable government regulation.

Key Market Players: Global Uveitis Drug Market

Few of the major competitors currently working in the global uveitis drug market are Xoma, Eye oint harmaceuticals, Novartis AG, Allergan, Enzo iochem Inc, Abbvie IncBausch & Lomb Pvt Ltd, Topivert Ltd, Santen harmaceutical Co., Ltd, Pfizer Inc, Johnson & Johnson Services, Inc,  Regeneron Pharmaceuticals, Inc, Hanall Biopharma, Daiichi sankyo company, limited, Alphamab Co. Ltd, Coherus BioSciences, Captisol, Clearside Biomedical, Eyegate, Eyevensys.

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-uveitis-drug-market

Market Definition: Global Uveitis Drug Market

Uveitis is the inflammatory diseases of the eye that produces swelling and damage the surrounding tissue of uvea, the middle layer of the eye that consist of choroid, ciliary body and iris. These diseases are not only limited to uvea but also affect the other eye parts like lens, retina and optic nerve producing slightly reduce vision or vision loss. A person with uveitis experiences blurred vision, dark, floating spots in the vision (floaters), eye pain, redness of the eye, sensitivity to light (photophobia) depending upon the type of inflammation.

Market Drivers

The global uveitis drug market is witnessing substantial growth due to increased aging population
Growing prevalence of uveitis and related complications
Introduction of innovative biologics, fast-track approval of pipeline drugs, increasing research and development investments in drug discovery and development
Rising government initiatives to minimize eye disorders are also driving the growth of the global uveitis drug market
Introduction of new routes for drug administration that improves the efficiency of the drug
With the advancement of molecular biology, some intravitreal implants and biologic agents are increasingly used for the treatment of uveitis
By the development of molecular biology, more therapeutic agents and approaches have been applied to control ocular inflammation caused by uveitis, which are expected to have a positive influence on the uveitis drug market

Market Restraints

The adverse effects related to uveitis treatment medication such as watery eyes, irritation and other factors
Poor primary healthcare infrastructure
Lack of awareness about eye disorders and lack of health insurance in developing countries are also obstructing the uveitis treatment market
Segmentation: Global Uveitis Drug Market

By Type

Anterior uveitis
Intermediate uveitis
Posterior uveitis
Panuveitis

By Mechanism of Action Type

Corticosteroids
Immunomodulators
Calcineurin inhibitors
Antimetabolites
Alkylating agents
T cell inhibitor
Antimicrobial
NSAIDS
Biologics
Intracameral Tissue Plasminogen Activator (TPA)
Others

By Route of Administration

Topical
Oral
Intravenous
Subcutaneous
Intramuscular
Intravitreal
Others

By End Users

Hospitals
Homecare
Specialty clinics
Surgical centers
Others

By Geography

North America
U.S.
Canada
Mexico
South America
Brazil
Argentina
Rest of South America
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Turkey
Belgium
Netherlands
Switzerland
Rest of Europe
Asia-Pacific
Japan
China
South Korea
India
Australia
Singapore
Thailand
Malaysia
Indonesia
Philippines
Rest of Asia-Pacific
Middle East & Africa
South Africa
Egypt
Saudi Arabia
United Arab Emirates
Israel
Rest of Middle East & Africa

Get TOC of Full Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-uveitis-drug-market

Key Developments in the Market

In October 2018, Eyepoint Pharmaceuticals received approval from the FDA for the fluocinolone acetonide intravitreal implant (Yutiq) for the treatment of chronic non-infectious uveitis that affects the posterior segment of the eye, as it delivers consistent dosing without the peaks
In July 2016, Abbvie Inc received approval for the drug Humira (adalimumab) non-corticosteroid therapy for non-infectious intermediate, posterior and panuveitis, as it shows early results of treatment when compared to other medications and it is the first approved biologic medication for uveitis
Competitive Analysis: Global Emphysema Drug Market

Global uveitis drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of uveitis drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.